You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,266,459


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,266,459
Title: Gaucher\'s disease: detection of a new mutation in intron 2 of the glucocerebrosidase gene
Abstract:A method for detecting a new Gaucher disease mutation in an allele in a human having a point mutation of an adenine nucleotide substituted for a guanine nucleotide at nucleotide position 1 in the normal glucocerebrosidase gene intron 2 is provided. Identification of the mutation is accomplished by first amplifying, with a polymerase chain reaction (PCR) primer, a region of human genomic DNA containing nucleotide position 1 of glucocerebrosidase gene intron 2 followed by detection of the mutation.
Inventor(s): Beutler; Ernest (La Jolla, CA)
Assignee: The Scripps Research Institute (La Jolla, CA)
Application Number:07/841,652
Patent Claims:1. A human genetic screening method for identifying a glucocerebrosidase gene mutation comprising detecting in a nucleic acid sample the presence of a glucocerebrosidase gene point mutation characterized as a substitution of an adenine nucleotide for a guanine nucleotide at nucleotide position 1 of glucocerebrosidase gene intron 2, thereby identifying said mutation.

2. The method according to claim 1 further comprising additionally detecting in a nucleic acid sample the presence of a glucocerebrosidase gene insertion mutation characterized as a insertion of an guanine nucleotide adjacent to nucleotide position 57 of glucocerebrosidase gene exon 2.

3. The method according to claim 1 further comprising additionally detecting in a nucleic acid sample the presence of a glucocerebrosidase gene point mutation characterized as a change from an adenine nucleotide to a guanine nucleotide at nucleotide position 2 of glucocerebrosidase gene exon 9.

4. The method according to claim 1 further comprising additionally detecting in a nucleic acid sample the presence of a glucocerebrosidase gene point mutation characterized as a change from a thymine nucleotide to a cytosine nucleotide at nucleotide position 60 of glucocerebrosidase gene exon 10.

5. A human genetic screening method for identifying a glucocerebrosidase gene mutation comprising:

(a) treating, under amplification conditions, a sample of genomic DNA from a human with a polymerase chain reaction (PCR) primer pair for amplifying a region of human genomic DNA containing nucleotide position 1 of glucocerebrosidase gene intron 2, said treating producing an amplification product containing said region; and

(b) detecting in the amplification product of step (a) the presence of an adenine (A) nucleotide point mutation at nucleotide position 1 of said intron, thereby identifying said mutation.

6. The method according to claim 5 wherein said region contains a nucleotide sequence represented by SEQ ID NO 2, or a fragment thereof.

7. The method according to claim 5 wherein said region consists essentially of a nucleotide sequence represented by SEQ ID NO 2.

8. The method according to claim 5 wherein said detecting comprises treating, under hybridization conditions, the amplification product of step (a) with an oligonucleotide probe specific for said point mutation, and detecting the formation of a hybridization product.

9. The method according to claim 8 wherein said oligonucleotide probe contains a nucleotide sequence represented by the formula, 5'-GGCATCAGATGAGTGAG-3' (SEQ ID NO 5).

10. The method according to claim 5 wherein said PCR primer pair produces an amplification product containing a preselected restriction enzyme site if said mutation is absent, and said detecting of step (b) comprises treating, under restriction conditions, the amplification product of step (a) with a restriction enzyme that recognizes said site, and detecting the presence of restriction products.

11. The method according to claim 5 wherein said PCR primer pair comprises:

(i) a first primer that hybridizes to an anti-sense strand within a region of human genomic DNA corresponding to exon 2 at a location 5' to nucleotide 88 said exon; and

(ii) a second primer that hybridizes to a sense strand of said intron 2 at a location 3' to nucleotide 1 of said intron.

12. The method according to claim 11 wherein said first primer of step (i) is represented by the formula, 5'-GAATGTCCCAAGCCTTTGA-3' (SEQ ID NO 3).

13. The method according to claim 11 wherein said second primer of step (ii) is represented by the formula, 5'-AAGCTGAAGCAAGAGAATCG-3' (SEQ ID NO 4).

14. The method according to claim 10 wherein said restriction enzyme is Hph I and said preselected restriction enzyme site is represented by the formula:

5'-GGTGA(N).sub.8 -3' (SEQ ID NO 6);

3'-CCACT(N).sub.7 -5' (SEQ ID NO 7);

where N can be A, C, G or T.

15. A method for detecting in a human a Gaucher disease allele containing a point mutation comprising substitution of an adenine (A) nucleotide for a guanine (G) at nucleotide position 1 of glucocerebrosidase gene intron 2, which method comprises:

(a) forming a polymerase chain reaction (PCR) admixture by combining, in a PCR buffer, a sample of genomic DNA from said human and a glucocerebrosidase gene-specific PCR primer pair defined by 5' and 3+ primers, said 5' primer priming within a region of human genomic DNA corresponding to nucleotide positions 1-88 of glucocerebrosidase gene exon 2, and said 3' primer priming within a region of human genomic DNA corresponding to nucleotide positions 2-270 of said glucocerebrosidase gene intron 2;

(b) subjecting said PCR admixture to a plurality of PCR thermocycles to produce a glucocerebrosidase gene amplification product;

(c) treating, under hybridization products produced in step (c), thereby detecting said mutation.

16. The method according to claim 15 wherein said 5' primer of step (a) is represented by the formula, 5'-GAATGTCCCAAGCCTTTGA-3' (SEQ ID NO 3).

17. The method according to claim 15 wherein said 3' primer of step (a) is represented by the formula, 5'-AAGCTGAAGCAAGAGAATCG-3' (SEQ ID NO 4).

18. The method according to claim 15 wherein said probe of step (c) is represented by the formula, 5'-GGCATCAGATGAGTGAG-3' (SEQ ID NO 5).

Details for Patent 5,266,459

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.